ScoreWhy is VYNE Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-51.38%
EBIT Growth (5y)
11.77%
EBIT to Interest (avg)
-28.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.14
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
63.83%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.71
EV to EBIT
0.31
EV to EBITDA
0.31
EV to Capital Employed
7.49
EV to Sales
-9.31
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2393.40%
ROE (Latest)
-96.29%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -25.74 MM
OPERATING PROFIT(Q)
Highest at USD -3.81 MM
PRE-TAX PROFIT(Q)
Highest at USD -3.58 MM
NET PROFIT(Q)
Highest at USD -3.58 MM
EPS(Q)
Highest at USD -0.08
-5What is not working for the Company
NET SALES(HY)
At USD 0.22 MM has Grown at -24.48%
CASH AND EQV(HY)
Lowest at USD 53.94 MM
DEBT-EQUITY RATIO
(HY)
Highest at -101.18 %
Here's what is working for VYNE Therapeutics, Inc.
Operating Cash Flow
Highest at USD -25.74 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD -3.81 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -3.58 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -3.58 MM has Grown at 46.36%
over average net sales of the previous four periods of USD -6.68 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -3.58 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Profit
At USD -3.58 MM has Grown at 46.36%
over average net sales of the previous four periods of USD -6.68 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.08
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Here's what is not working for VYNE Therapeutics, Inc.
Net Sales
At USD 0.22 MM has Grown at -24.48%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Cash and Eqv
Lowest at USD 53.94 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -101.18 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
